Reviewed by Michael Gill, B. Sc.
Image of Los Angeles Biomedical Reaearch Institute at Harbor-UCLA Medical Center in Torrance, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Minocyclinefor Diabetic Nephropathy

18+
All Sexes
Diabetic kidney disease increases the risk of illness and death from heart disease in patients with Type 2 diabetes. Some blood pressure medications called ACE inhibitors and ARBs slow progression of kidney disease, but the dose that can be used is often limited by side effects that are experienced by patients. The most limiting side effects of the current treatments are lowering of the kidney function or blood pressure, and a rise in blood potassium levels. A safe and inexpensive medication that doesn't lower kidney function or blood pressure or raise serum potassium would be useful. Minocycline is a tetracycline antibiotic with recently appreciated protective properties. In a published journal article by Dr. Isermann, minocycline prevented the death of specialized kidney cells in mice. The kidneys of these mice did not develop diabetic kidney disease when seen under the microscope and the mice experienced only a little bit of protein loss in the urine. In a different published paper, the authors showed that minocycline also decreased kidney injury in a model of non-diabetic kidney disease. A related tetracycline antibiotic was shown to lower urine protein in diabetic patients. These data support a rationale for testing to see if minocycline is safe and helpful in patients with diabetic kidney disease. In this study, all patients will stay on their usual medications for the treatment of diabetic kidney disease. Patients will be given either minocycline (100 mg by mouth twice a day for 24 weeks) or placebo (an inactive capsule taken twice a day for 24 weeks). Minocycline or placebo will be assigned by a process called "randomization", which is like a coin toss. Neither the patient nor the study team will know if the patient is taking placebo or minocycline until the end of the study. The study will assess minocycline safety and test to see if minocycline is helpful or not helpful for the treatment of diabetic kidney disease. This study was funded by the American Diabetes Association and is not supported by any pharmaceutical company.
Waitlist Available
FDA Approved Drug
Los Angeles Biomedical Reaearch Institute at Harbor-UCLA Medical CenterSharon G Adler, MD
10 Diabetic Nephropathy Clinical Trials Near Me
Top Hospitals for Diabetic Nephropathy Clinical Trials
Image of Mayo Clinic in Rochester in Minnesota.
Mayo Clinic in Rochester
Rochester
3Active Trials
3All Time Trials for Diabetic Nephropathy
2018First Diabetic Nephropathy Trial
Image of Medical College of Wisconsin in Wisconsin.
Medical College of Wisconsin
Milwaukee
1Active Trials
1All Time Trials for Diabetic Nephropathy
2022First Diabetic Nephropathy Trial
Top Cities for Diabetic Nephropathy Clinical Trials
Image of Victorville in California.
Victorville
2Active Trials
Kidney & Hypertension CenterTop Active Site
Diabetic Nephropathy Clinical Trials by Phase of Trial
Top Treatments for Diabetic Nephropathy Clinical Trials
Treatment Name
Active Diabetic Nephropathy Clinical Trials
All Time Trials for Diabetic Nephropathy
First Recorded Diabetic Nephropathy Trial
Individualized basic need navigation and lifestyle coaching
1
1
2022
Fenofibrate
1
3
2016
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion
1
1
2021
BI 685509
1
2
2017
Pegloticase 8 MG/ML [Krystexxa]
1
1
2020
Recently Completed Studies with FDA Approved Treatments for Diabetic Nephropathy
Treatment
Year
Sponsor
CSL346
2020
CSL Behring

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, Tuazon J, Safdi A, Scialla J, Susztak K, Isakova T. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney Int Rep. 2018 Sep 18;4(1):94-102. doi: 10.1016/j.ekir.2018.09.006. eCollection 2019 Jan. https://pubmed.ncbi.nlm.nih.gov/305961722 Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. https://pubmed.ncbi.nlm.nih.gov/210529783 Shah AP, Shen JI, Wang Y, Tong L, Pak Y, Andalibi A, LaPage JA, Adler SG. Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial. PLoS One. 2016 Mar 28;11(3):e0152357. doi: 10.1371/journal.pone.0152357. eCollection 2016. https://pubmed.ncbi.nlm.nih.gov/27019421